MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918)

NCT01028586 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
507
Enrollment
INDUSTRY
Sponsor class

Stopped Trial is terminated due to a company decision to return all rights for Safinamide back to Newron Pharmaceuticals

Conditions

Interventions

Sponsor

Newron Pharmaceuticals SPA